Abstract
Osteoarthritis (OA) is a degenerative joint disorder and is the leading cause of disability of people, which negatively impact people’s physical and mental health. Although OA causes great socioeconomic burden and individual suffering, no effective treatment options are provided so far. This is partially resulted from poor regenerative activity of articular cartilage and our incomplete understanding of the underlying mechanism of OA. Traditional drug therapies such as acetaminophen and opioids are effective in relieving pain but do not reverse cartilage damage and are often associated with adverse events. Therefore, it is necessary to find effective OA drugs. In recent years, novel regenerative therapies have received much attention because they can effectively promote tissue repair and regeneration. The fibroblast growth factor (FGF) signaling has been suggested to involve in cartilage homeostasis for decades. The current research shows that sprifermin/recombinant FGF18 significantly reduces the loss of cartilage thickness and volume without serious side effects, thus warrants a continued research for potential new medications of OA. This review mainly highlights the current research progress on FGFs and FGF receptors as a potential therapeutic target for OA.
| Original language | English |
|---|---|
| Pages (from-to) | 2-10 |
| Number of pages | 9 |
| Journal | Chinese Journal of Physiology |
| Volume | 62 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2019 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Physiology
- Physiology (medical)
Cite this
}
Fibroblast growth factors : Potential novel targets for regenerative therapy of osteoarthritis. / Chen, Tsung Ming; Chen, Ya Huey; Sun, Hsiao-Fang; Tsai, Shaw-Jenq.
In: Chinese Journal of Physiology, Vol. 62, No. 1, 01.01.2019, p. 2-10.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Fibroblast growth factors
T2 - Potential novel targets for regenerative therapy of osteoarthritis
AU - Chen, Tsung Ming
AU - Chen, Ya Huey
AU - Sun, Hsiao-Fang
AU - Tsai, Shaw-Jenq
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Osteoarthritis (OA) is a degenerative joint disorder and is the leading cause of disability of people, which negatively impact people’s physical and mental health. Although OA causes great socioeconomic burden and individual suffering, no effective treatment options are provided so far. This is partially resulted from poor regenerative activity of articular cartilage and our incomplete understanding of the underlying mechanism of OA. Traditional drug therapies such as acetaminophen and opioids are effective in relieving pain but do not reverse cartilage damage and are often associated with adverse events. Therefore, it is necessary to find effective OA drugs. In recent years, novel regenerative therapies have received much attention because they can effectively promote tissue repair and regeneration. The fibroblast growth factor (FGF) signaling has been suggested to involve in cartilage homeostasis for decades. The current research shows that sprifermin/recombinant FGF18 significantly reduces the loss of cartilage thickness and volume without serious side effects, thus warrants a continued research for potential new medications of OA. This review mainly highlights the current research progress on FGFs and FGF receptors as a potential therapeutic target for OA.
AB - Osteoarthritis (OA) is a degenerative joint disorder and is the leading cause of disability of people, which negatively impact people’s physical and mental health. Although OA causes great socioeconomic burden and individual suffering, no effective treatment options are provided so far. This is partially resulted from poor regenerative activity of articular cartilage and our incomplete understanding of the underlying mechanism of OA. Traditional drug therapies such as acetaminophen and opioids are effective in relieving pain but do not reverse cartilage damage and are often associated with adverse events. Therefore, it is necessary to find effective OA drugs. In recent years, novel regenerative therapies have received much attention because they can effectively promote tissue repair and regeneration. The fibroblast growth factor (FGF) signaling has been suggested to involve in cartilage homeostasis for decades. The current research shows that sprifermin/recombinant FGF18 significantly reduces the loss of cartilage thickness and volume without serious side effects, thus warrants a continued research for potential new medications of OA. This review mainly highlights the current research progress on FGFs and FGF receptors as a potential therapeutic target for OA.
UR - http://www.scopus.com/inward/record.url?scp=85064135158&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064135158&partnerID=8YFLogxK
U2 - 10.4103/CJP.CJP_11_19
DO - 10.4103/CJP.CJP_11_19
M3 - Review article
C2 - 30942193
AN - SCOPUS:85064135158
VL - 62
SP - 2
EP - 10
JO - Chinese Journal of Physiology
JF - Chinese Journal of Physiology
SN - 0304-4920
IS - 1
ER -